TPR

Across TCGA pan-cancer cohorts, TPR mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TPR data layer compared with 25 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TPR mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TPR expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

HNSC, COAD, and LUAD are the cancer types where TPR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.757	0.933	.002	39	view →
COAD	DFS	Median	II,III,IV	1.000	0.884	.025	24	view →
LUAD	OS	Tertile	All	0.909	0.706	.012	24	view →
CCRCC	OS	Median	III,IV	0.578	0.882	.004	24	view →
LSCC	OS	Median	All	0.874	0.705	.018	8	view →
PDAC	OS	Median	IV	0.951	0.381	.006	6	view →
OV	DFS	Median	All	1.000	0.864	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TPR–HNSC (OS)

Open the HNSC breakdown →